



CHARLIE CRIST
GOVERNOR

Better Health Care for all Floridians

ELIZABETH DUDEK
INTERIM SECRETARY

Purpose of the Bone Marrow Transplant Advisory Panel:

Florida Statute 627.4236 requires the Agency for Health Care Administration to adopt rules specifying the bone marrow transplant procedures that are accepted within the appropriate oncological specialty and are not experimental for purposes of determining coverage by an insurer or a health maintenance organization. The rules must be based upon the recommendations of an advisory panel appointed by the Secretary of the Agency.

- 1) The panel must take into account findings, studies, or research of the Federal Agency for Health Care Policy, National Cancer Institute, National Academy of Sciences, Health Care Financing Administration, and Congressional Office of Technology Assessment, and any other relevant information,
- 2) Consider whether the federal Food and Drug Administration or National Cancer Institute is conducting or sponsoring assessment procedures to determine the safety and efficacy of the procedure or substantially similar procedures, or of any part of such procedures.
- 3) Consider practices of providers with respect to requesting or requiring patients to sign a written acknowledgment that a bone marrow transplant procedure is experimental.

The advisory panel shall conduct, at least biennially, a review of scientific evidence to ensure that its recommendations are based on current research findings and that insurance policies offer coverage for the latest medically acceptable bone marrow transplant procedures.

The Agency for Health Care Administration, on behalf of the Bone Marrow Transplant Advisory Panel, announces a public meeting to which all persons are invited.

DATE AND TIME: October 29, 2010, 9:00 a.m.

PLACE: Agency for Health Care Administration, 2727 Mahan Drive, Building 3, Conference Room B, Tallahassee, FL 32308

GENERAL SUBJECT MATTER TO BE CONSIDERED: The Bone Marrow Transplant Advisory Panel will discuss recommendations regarding the bone marrow transplant procedures that are accepted within the appropriate oncological specialty and are not experimental; and any recommended changes to rule 59B-12.001, defining those treatments that are appropriate for coverage by insurers.

A copy of the agenda may be obtained by contacting: Elizabeth Tull, Bureau of Managed Health Care (850) 412-4317

